Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group-Reference-Cited by-同舟云学术

Relapsed/refractory pediatric B-cell non-Hodgkin lymphoma treated with rituximab combination therapy: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group

Published:2016-06-17 Issue:10 Volume:63 Page:1794-1799
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Osumi Tomoo¹,Mori Tetsuya²,Fujita Naoto³,Saito Akiko M.⁴,Nakazawa Atsuko⁵,Tsurusawa Masahito⁶,Kobayashi Ryoji⁷

Affiliation:

1. Children's Cancer Center; National Center for Child Health and Development

2. Department of Pediatrics; St. Marianna University School of Medicine

3. Department of Pediatrics; Hiroshima Red Cross Hospital & Atomic-Bomb Survivors Hospital

4. Clinical Research Center; National Hospital Organization Nagoya Medical Center

5. Department of Pathology; National Center for Child Health and Development

6. Department of Pediatrics; Ama City Hospital

7. Department of Pediatrics; Sapporo Hokuyu Hospital

Funder

Japan Agency for Medical Research and Development

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference28 articles.

1. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia;Patte;Blood,2001

2. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90;Reiter;Blood,1999

3. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients;Patte;Blood.,2007

4. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study;Gerrard;Br J Haematol,2008

5. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents;Cairo;Blood,2007

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma in Children, Adolescents, and Young Adults;Journal of the National Comprehensive Cancer Network;2024-07

2. Refractory Burkitt Lymphoma: Diagnosis and Interventional Strategies;Blood and Lymphatic Cancer: Targets and Therapy;2024-03

3. The experience of relapsed Burkitt lymphoma treatment with targeted drugs and autologous/allogeneic stem cell transplantation;Oncohematology;2024-01-25

4. Ibrutinib plus RICE or RVICI for relapsed/refractory mature B-cell non-Hodgkin lymphoma in children and young adults: SPARKLE trial;Blood Advances;2023-02-20

5. Use of gemcitabine, oxaliplatin, and anti‐CD20 therapy in children and adolescents with non‐Hodgkin lymphoma unfit for intensive therapy;Pediatric Blood & Cancer;2023-01-24